Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.86 USD
Change Today -0.085 / -0.50%
Volume 1.4M
HALO On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $17.27
52 Week Low
04/28/14 - $6.88
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

halozyme therapeutics inc (HALO) Related Businessweek News

No Related Businessweek News Found

halozyme therapeutics inc (HALO) Details

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer; and Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxter Healthcare Corporation, Pfizer Inc., and Janssen Biotech, Inc. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

153 Employees
Last Reported Date: 03/2/15
Founded in 1998

halozyme therapeutics inc (HALO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.6M
Chief Financial Officer and Vice President
Total Annual Compensation: $364.9K
Compensation as of Fiscal Year 2014.

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics Appoints Harry J. Leonhardt, Esq. as Senior Vice President, General Counsel and Chief Compliance Officer

Halozyme Therapeutics, Inc. announced the appointment of Harry J. Leonhardt, Esq., as senior vice president, general counsel and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive officer. Mr. Leonhardt brings more than 30 years of corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience to Halozyme, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals. At Halozyme, he will be responsible for all legal, compliance and intellectual property matters. Prior to joining Amylin, Mr. Leonhardt served as senior vice president, general counsel and corporate secretary for Senomyx; executive vice president of Business Development, general counsel and corporate secretary at Genoptix, Inc.; and senior vice president, general counsel and secretary for Nanogen, Inc.

Halozyme Therapeutics, Inc. Announces Plans to Proceed with Phase 3 Clinical Study

Halozyme Therapeutics, Inc. announced it plans to proceed with a Phase 3 clinical study (Study 301) of its investigational new drug PEGPH20 in patients with metastatic pancreatic cancer, using a design allowing for potential marketing application based on either progression free survival (PFS) or overall survival. The use of PFS as the basis for marketing approval will be subject to the overall benefit and risk associated with PEGPH20 combined with nab-paclitaxel (ABRAXANE) and gemcitabine therapy, including the: Magnitude of the PFS treatment effect observed; Toxicity profile; and Interim overall survival data. The study will enroll patients whose tumors accumulate high levels of hyaluronan (HA) – a sugar that is sometimes more prevalent in the areas surrounding cancer cells.

Halozyme Therapeutics, Inc. Announces the Appointment of James S. Mazzola as Vice President, Corporate Communications and Investor Relations

Halozyme Therapeutics, Inc. announced the appointment of James S. Mazzola as vice president, Corporate Communications and Investor Relations, reporting to President and CEO Dr. Helen Torley. Mr. Mazzola will be responsible for the creation and implementation of integrated communication and branding efforts that support Halozyme's business objectives to all key stakeholders, including investors, employees, media, corporate partners, patients, clinicians and the scientific community. Mr. Mazzola brings nearly 25 years of public relations, financial communication and marketing communication experience to Halozyme. He was previously senior vice president of Global Marketing, Communication and Investor Relations for CareFusion, responsible for the company's integrated marketing, communication and brand strategy, investor relations, sales operations and serving as president of the CareFusion Foundation. Prior to joining CareFusion, he was senior vice president of Global Communication at Cardinal Health where he led corporate public relations, financial communication and the Cardinal Health Foundation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $16.86 USD -0.085

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $15.25 USD -0.04
Valeant Pharmaceuticals International Inc C$255.98 CAD +1.76
View Industry Companies

Industry Analysis


Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.0x
Price/Book 51.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at